Neurofibromatosis type 1 (NF1) and pheochromocytoma: Prevalence, clinical and cardiovascular aspects

Archives of Dermatological Research

Volumn 303, Issue 5, 2011, Pages 317-325

  Zinnamosca, Laura ^a   Petramala, Luigi ^a   Cotesta, Dario ^a   Marinelli, Cristiano ^a   Schina, Mauro ^a   Cianci, Rosario ^a   Giustini, Sandra ^a   Sciomer, Susanna ^a   Anastasi, Emanuela ^b   Calvieri, Stefano ^a   De Toma, Giorgio ^a   Letizia, Claudio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiovascular diseases; Neurofibromatosis type 1; Pheochromocytoma

Indexed keywords

METADRENALIN; VANILMANDELIC ACID;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; NEUROFIBROMATOSIS; PHEOCHROMOCYTOMA; PREVALENCE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ADRENAL GLAND NEOPLASMS; ADRENAL MEDULLA; ADULT; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BODY MASS INDEX; CARDIOVASCULAR SYSTEM; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; MALE; METANEPHRINE; MIDDLE AGED; NEUROFIBROMATOSIS 1; PHEOCHROMOCYTOMA; PREVALENCE; VANILMANDELIC ACID;

EID: 79959538593     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-010-1090-z     Document Type: Article

References (35)

1. Bausch B, Borozdin W, Mautner VF et al (2007) Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 92(7):2784-2792 (Pubitemid 47037390)
2. Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24:539-553 (Pubitemid 37056243)
3. Ceruti M, Petramala L, Cotesta D et al (2006) Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal diseases. J Clin Hypertens 8:642-648
4. Cichowski K, Jacks T (2001) NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593-604 (Pubitemid 32201953)
5. Cotesta D, Erlic Z, Petramala L et al (2008) Coincidence of neurofibromatosis Type 1 and multiple endocrine neoplasia type 2. Endocrinologist 18:277-281
6. Denolle T, Chatellier G, Julien J et al (1993) Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 6:907-913 (Pubitemid 23363177)
7. Ferner RE, Huson SM, Thomas N et al (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44(2):81-88
8. Friedman JM (1999) Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6
9. Gabriel KR (1997) Neurofibromatosis. Curr Opin Pediatr 9:89-93
10. Goldberg NS, Roenigk RK (1996) Neurofibromatosis, tuberous sclerosis, and other neurocutaneous discorde. In: Wintronb BU (ed) Cutaneous medicine and surgery: an interpretated program in dermatology. WB Saunders, Philadelpfia, pp 1729-1741
11. Goldstein DS, Eisenhofer G, Flynn JA et al (2004) Diagnosis and localization of pheochromocytoma. Hypertension 43:907-910 (Pubitemid 38579886)
12. Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51-57 (Pubitemid 27274517)
13. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C (2006) Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 19(3):243-250 (Pubitemid 43261503)
14. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589-600 (Pubitemid 44325350)
15. Heniford BT, Arca MJ, Walsh RM, Gill IS (1999) Laparoscopic adrenalectomy for cancer. Semin Surg Oncol 16(4):293-306 (Pubitemid 29226844)
16. Huson SM, Compston DA, Clark P et al (1989) A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 26:704-711 (Pubitemid 19270599)
17. Ito Y, Fujimoto Y, Obara T (1992) The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg 16:759-763
18. Jenne DE, Tinschert S, Reimann H et al (2001) Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J Hum Genet 69:516-527 (Pubitemid 32777691)
19. Kurpad AV, Khan K, Calder AG, Elia M (1994) Muscle and whole body metabolism after norepinephrine. Am J Physiol 266:E877-E884
20. La Batide-Alanore A, Chatellier G, Plouin PF (2003) Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertension 21:1703-1707 (Pubitemid 37076354)
21. Lakkis MM, Epstein JA (1998) Neurofibromin modulation of Ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125:4359-4367 (Pubitemid 28564281)
22. Lenders JW, Eisenhofer G, Mannelli M et al (2005) Phaeochromocytoma. Lancet 366:665-675 (Pubitemid 41176020)
23. Mancia G, Ferrari A, Gregorini L et al (1983) Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53:96-104 (Pubitemid 13031772)
24. Mannelli M, Ianni L, Cilotti A et al (1999) Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141:619-624 (Pubitemid 30064762)
25. Millar-Craig MW, Bishop CN, Raftery EB (1978) Circadian variation of blood-pressure. Lancet 1:795-797
26. Norton KK, Xu J, Gutmann DH (1995) Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 2:13-21
27. O'Brien E, Sheridan J, O'Malley K (1988) Dippers and non-dippers. Lancet 2:397
28. Pacak K, Linehan WM, Eisenhofer G et al (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315-329 (Pubitemid 32163955)
29. Palatini P, Penzo M, Racioppa A et al (1992) Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med 152:1855-1860
30. Rizzoni D, Muiesan ML, Porteri E et al (1998) Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 32:985-992 (Pubitemid 28459589)
31. Routledge F, McFetridge-Durdle J (2007) Non-dipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs 6:9-26
32. Shub C, Cueto-Garcia L, Sheps SG et al (1986) Echocardiographic findings in pheochromocytoma. Am J Cardiol 57:971-975 (Pubitemid 16055645)
33. Tedesco MA, Di Salvo G, Natale F, Pergola V, Calabrese E, Grassia C, Ratti G, Iarussi D, Iacono A, Calabrò R, Lama G (2002) The heart in neurofibromatosis type 1: an echocardiographic study. Heart J. 143:883-888 (Pubitemid 34595349)
34. Walther MM, Herring J, Enquist E et al (1999) von Recklinghausen's disease and pheochromocytomas. J Urol 162:1582-1586 (Pubitemid 29474665)
35. Xu J, Ismat FA, Wang T et al (2009) Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res 105:304-311